Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in female patients with non-ST-segment elevation acute coronary syndrome

Chinese Medical Journal

Volumn 125, Issue 13, 2012, Pages 2250-2254

  Gao, Yuan ^a   Jia, Zhi mei ^a   Sun, Yu jiao ^a   Zhang, Zhi hong ^a   Ren, Li na ^a   Qi, Guo xian ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Acute coronary syndrome; Angioplasty; Female; Inflammation; Rosuvastatin

Indexed keywords

ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART DEATH; HEART DISEASE; HEART INFARCTION; HEART MUSCLE INJURY; HUMAN; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION;

ACUTE CORONARY SYNDROME; AGED; C-REACTIVE PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-1; INTERLEUKIN-6; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PYRIMIDINES; SULFONAMIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863793787     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.13.002     Document Type: Article

References (21)

1. Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Trynosky K, Diercks DB, et al. For the CRUSADE Investigators: Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. J Am Coll Cardiol 2005; 45: 832-837.
2. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-1718.
3. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005; 46: 1405-1410.
4. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007; 49: 1272-1278.
5. Yun KH, Shin IS, Park EM. Effect of additional statin therapy on endothelial function and prognosis in patients with vasospastic angina. Korean Circ J 2008; 38: 638-643.
6. Nishino M, Hoshida S, Kato H, Egami Y, Shutta R, Yamaguchi H, et al. Preprocedural statin administration can reduce thrombotic reaction after stent implantation. Circ J 2008; 72: 232-237.
7. Thygesen K, Alpert JS, White HD. On behalf of the joint ESC/ACCF/AHA/WHF task force for the redefinition of myocardial infarction. Universal definition of myocardial infarction. J Am Coll Cardiol 2007; 50: 2173-2195.
8. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005; 111: 3481-3488.
9. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876-1890.
10. Rus HG, Vlaicu R, Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 1996; 127: 263-271.
11. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002; 347: 5-12.
12. Balbay Y, Tikiz H, Baptiste RJ, Ayaz S, Sasmaz H, Korkmaz S. Circulating IL-1 beta, IL-6, TNF alpha and soluble ICAM-1 in patients witch chronic stable angina and myocardial infarction. Angiology 2001; 52: 109-114.
13. Bonz AW, Lengenfelder B, Jacobs M, Strotmann J, Held S, Ertl G, et al. Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein IIb/IIIa receptor antagonism. Am Heart J 2003; 145: 693-699.
14. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine-kinase MB fraction after percutaneous coronary interventions. Circulation 1996; 94: 1528-1536.
15. Morikawa S, Takabe W, Mataki C, Kanke T, Itoh T, Wada Y, et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 2002; 9: 178-183.
16. Stenestrand U, Wallentin L. Early statin treatment following acutemyocardial infarction and 1-year survival. JAMA 2001; 285: 430-436.
17. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACLE study. A randomized conrolled trial. JAMA 2001; 285: 1711-1718.
18. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Eng J Med 2004; 350: 1495-1504.
19. Sun Y, Qi G, Gao Y, Zhang H, Pang X, Zhao W, et al. Effect of different loading doses of atorvastatin on percutaneous coronary intervention for acute coronary syndromes. Can J Cardiol 2010; 26: 481-485.
20. Yun KH, Jeong MH, Oh SK, Rhee SJ, Park EM, Lee EM, et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol 2009; 137: 246-251.
21. Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes. Mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol 2002; 22: 1524-1534.